Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| XLV | TUSHEALTH-A | |
|---|---|---|
| Held by both | ||
 Eli Lilly and Co | 15.10% | 14.91% |
 Johnson & Johnson | 10.41% | 10.28% |
 AbbVie | 7.54% | 7.45% |
 Merck & | 5.85% | 5.77% |
 UnitedHealth Group | 5.38% | 5.31% |
 Amgen Inc | 3.72% | 3.67% |
 Gilead Sciences Inc | 3.02% | 2.98% |
 Abbott Laboratories | 2.79% | 2.75% |
 Pfizer Inc | 2.65% | 2.62% |
| Only in XLV | ||
 Thermo Fisher Scientific Inc | 4.07% | N/A |
| Only in TUSHEALTH-A | ||
| Thermo Fisher | N/A | 4.02% |
30 Dec 2025 → 3 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| XLV | +20.34% | 16.81% | 1.21 |
| TUSHEALTH-A | +15.29% | 16.09% | 0.95 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | XLV | TUSHEALTH-A |
|---|---|---|
Fund details | ||
| Fund size | N/A | 455 million |
| Inception date | N/A | 18 Sep 2024 |
| Master fund | N/A | กองทุน State Street Health Care Select Sector SPDR ETF |
| Dividend policy | N/A | Does not pay |
Risk and currency hedging | ||
| Risk level | N/A | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion |
| Share hedged | N/A | 88.99% |
Minimum purchase and redemption | ||
| First purchase | N/A | 1,000 THB |
| Subsequent purchase | N/A | 1,000 THB |
| Redemption (amount) | N/A | No minimum |
| Redemption (units) | N/A | No minimum |
| Balance (amount) | N/A | No minimum |
| Balance (units) | N/A | 100 units |
Order cut-off and redemption payment | ||
| Buy before | N/A | 15:30 |
| Redeem before | N/A | 15:30 |
| Redemption paid | N/A | T+3 |
